Effect of Supplemental Lutein and Zeaxanthin on Serum, Macular Pigmentation, and Visual Performance in Patients with Early Age-Related Macular Degeneration
Table 3
Changes of visual performance among different groups during the interventiona.
Placebo (
10 mg lutein ()
20 mg lutein ()
10 mg lutein + 10 mg zeaxanthin ()
Best-corrected visual acuity,
Baseline
0.34 ± 0.19
0.31 ± 0.21
0.31 ± 0.21
0.32 ± 0.25
24 weeks
0.33 ± 0.25
0.32 ± 0.21
0.27 ± 0.17
0.28 ± 0.30
48 weeks
0.34 ± 0.22
0.28 ± 0.22
0.26 ± 0.20
0.27 ± 0.35
2 years
0.30 ± 0.25
0.26 ± 0.15
0.28 ± 0.16
0.27 ± 0.24
Photorecovery time, sec
Baseline
18.57 ± 16.78
16.68 ± 14.22
15.86 ± 11.17
17.38 ± 12.00
24 weeks
19.02 ± 10.59
18.90 ± 17.71
14.13 ± 8.11
16.41 ± 14.69
48 weeks
19.70 ± 12.16
15.50 ± 11.27
14.61 ± 13.43
17.80 ± 16.48
2 years
24.41 ± 14.40
15.00 ± 8.40†
15.36 ± 12.75†
15.67 ± 11.04
VFQ25 score
Baseline
76.04 ± 18.09
75.46 ± 14.60
75.58 ± 15.35
74.26 ± 14.46
48 weeks
74.97 ± 17.10
75.02 ± 13.01
72.56 ± 14.46
76.32 ± 11.20
2 years
77.31 ± 17.05
79.61 ± 13.52
76.65 ± 16.32
80.13 ± 11.73**
: logarithm of minimum angle of resolution; VFQ25: Visual Function Questionnaire 25. All values are mean ± SDs. Mean values were significantly different from baseline within the same group: . Mean values were significantly different from those of the placebo control group: .
aRepeated-measures analyses of the above variables did not reveal any differential treatment or time effects.
